End-use Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)

Hospital pharmacies led the osteoarthritis injectables market in 2026, accounting for a 50.5% share, owing to their close connection with orthopedic care, specialist consultations, and procedures requiring injectable therapies. Hospitals provide an integrated environment where physicians can assess disease severity, determine appropriate treatment, and coordinate medication administration with broader patient care. The availability of trained healthcare professionals and controlled medication handling further supports the use of injectable osteoarthritis treatments through hospital pharmacies. Continued demand for supervised treatment and specialist-led management reinforces the segment's leading position.

Retail pharmacies are the fastest-growing end-use segment, supported by the broader movement toward convenient and accessible medication distribution outside hospital settings. As osteoarthritis management increasingly incorporates outpatient care, retail pharmacies can improve access to prescribed therapies and reduce dependence on hospital-based medication procurement. Their proximity to patients and established role in community healthcare make them particularly relevant for individuals requiring ongoing treatment. Expansion of decentralized healthcare delivery and increasing preference for convenient access are contributing to the segment's growth.

Anatomy Segment Analysis: Knee Osteoarthritis (Largest Segment) vs Hip Osteoarthritis (Fastest-Growing Segment)

The knee osteoarthritis segment accounted for the largest share of the osteoarthritis injectables market in 2026, reaching 44.48%, reflecting the substantial therapeutic demand associated with knee joint degeneration and its impact on mobility and daily activities. Injectable therapies are increasingly considered as part of comprehensive management strategies aimed at reducing joint discomfort and supporting physical function. The need to manage persistent symptoms while delaying or avoiding more invasive interventions can contribute to demand for injectable treatment options. Greater awareness of osteoarthritis management and continued use of non-surgical approaches further support the segment's leading position.

Hip osteoarthritis is the fastest-growing anatomical segment, driven by increasing attention to treatment options that can address pain and functional limitations associated with hip joint degeneration. As patients and healthcare providers place greater emphasis on maintaining mobility and managing osteoarthritis before more invasive procedures become necessary, interest in therapeutic interventions is expanding. Advances in treatment approaches and growing focus on individualized management are supporting broader consideration of injectable options. The increasing clinical attention given to hip-related osteoarthritis is consequently strengthening demand within this segment.